Developmental Research Program

$111,504P50FY2025CANIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 39565979 Paper 39516648 Paper 39461879 Paper 39281316 Paper 39137006 Paper 38938748 Paper 38921956 Paper 38672668 Paper 38458639 Paper 38236069 Paper 38077030 Paper 38039877 Paper 37880008 Paper 37857525 Paper 37819945 Paper 37713508 Paper 37694289 Paper 37645831 Paper 37566492 Paper 37552475 Paper 36963232 Paper 36756942 Paper 36750253 Paper 36694401 Paper 36543958 Paper 36383142 Paper 36330485 Paper 36323258 Paper 36315045 Paper 36275862 Paper 36165913 Paper 35930654 Paper 35618721 Paper 35587532 Paper 35404482 Paper 35392082 Paper 35286200 Paper 35091445 Paper 35058175 Paper 35040434 Paper 34965932 Paper 34921143 Paper 34732714 Paper 34715452 Paper 34660908 Paper 34642315 Paper 34525351 Paper 34083421 Paper 34077698 Paper 33986123 Paper 33886544 Paper 33667223 Paper 33614939 Paper 33589820 Paper 33539547 Paper 33507235 Paper 33483333 Paper 33398183 Paper 33203730 Paper 32680952 Paper 32661362 Paper 32545260 Paper 32415114 Paper 32329924 Paper 32276964 Paper 32205483 Paper 32124417 Paper 32065978 Paper 32065467 Paper 31983262 Paper 31965091 Paper 31924475 Paper 31800111 Paper 31683169 Paper 31671769 Paper 31661135 Paper 31613686 Paper 31604537 Paper 31547706 Paper 31471106 Paper 31422216 Paper 31422205 Paper 31308059 Paper 31194275 Paper 31183606 Paper 31150317 Paper 30967541 Paper 30828910 Paper 30811896 Paper 30773733 Paper 30683880 Paper 30683736 Paper 30648929 Paper 30647454 Paper 30642285 Paper 30592624 Paper 30527235 Paper 30449525 Paper 30419129 Paper 30409313

Abstract

The Developmental Research Program (DRP) of the UPMC Hillman Cancer Center (HCC) Head and Neck (HN) SPORE seeks to fund and facilitate translationally driven, innovative pilot projects in head and neck squamous cell carcinoma (HNSCC). The overarching goal is to decrease HNSCC morbidity and mortality through stimulating new research in the areas of prevention and early detection; mechanisms of tumorigenesis and therapeutic resistance; predictive and prognostic biomarkers; and novel targets and approaches to therapy. To accomplish this goal, we will build on our successful program that, in this current funding cycle, supported 15 awards that subsequently contributed to 42 publications, 9 external grants, 3 patents, 6 inventions and 2 clinical trials, with a return on investment of 27.2 (ie. for every dollar invested 27.2 were returned). Biannually, we will widely solicit proposals from investigators new to HNSCC research as well as from established HNSCC investigators with highly innovative ideas. Members of the Internal and External Advisory Boards will be encouraged to identify investigators outside of the HCC HN SPORE who could serve as potential collaborators. The most meritorious proposals submitted will be selected based on an NIH-style two-tiered review to ensure rigor, with support coming from both SPORE funds and institutional commitment. DRP awardees new to HNSCC will be assigned an experienced mentor to provide guidance and integration into the SPORE. All DRP awardees will report annually on the progress of their projects and those that demonstrate significant research progress will be eligible for competitive renewal for a second year. Should the need arise, exceptional pilots with potential for significant translational impact can be elevated to full SPORE projects. Indeed, two of the three full SPORE projects in this renewal came from DRP pilots.

View original record on NIH RePORTER →